At present, one PPARα agonist (a.k.a. Pemafibrate) and three pan-PPAR agonists (a.k.a. Lanifibranor, Pioglitazone, and Saroglitazar) are under clinical trials as drugs for NASH treatment respectively (88–91). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.